Biohaven (BHVN) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Biohaven (BHVN) over the past year, gaining 113.4% versus a loss of 22.2%. Biohaven is the larger company by market cap ($1.82 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | URGN |
|---|---|---|
| Share price | $12.08 | $36.83 |
| Market cap | $1.82B | $1.80B |
| 1-day change | +1.26% | -0.41% |
| YTD return | +5.67% | +57.90% |
| 1-year return | -22.23% | +113.39% |
| 5-year return | — | +117.27% |
| Forward P/E | — | 13.18 |
| EPS (TTM) | $-4.56 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-738.82M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $18.57 | $50.81 |
| 52-week low | $7.48 | $15.86 |
| Distance from 52-week high | -34.93% | -27.51% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +76.08% | +62.91% |
| Average volume | 2.62M | 849.01K |
| Shares outstanding | 151.04M | 48.88M |
| Employees | 274 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed BHVN by 135.6 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
BHVN vs URGN FAQ
Which is bigger, Biohaven or UroGen Pharma?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.80B for UroGen Pharma (URGN).
Which stock has performed better over the past year, BHVN or URGN?
URGN returned +113.39% over the past 12 months, compared with -22.23% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.